Who are tranexamic acid (Exacyl®)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Trasylol, Cyklokapron, Amicar, Tranexamic Acid Irrigation, Tranexamic Acid Dosage 1, aPCC, aPCC + TXA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tranexamic-acid-exacyl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

tranexamic acid (Exacyl®) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

tranexamic acid (Exacyl®) (tranexamic acid (Exacyl®)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antifibrinolytic. Area: Oncology, Surgery.

phase 3 Antifibrinolytic Lysine receptor on plasminogen Oncology, Surgery Small molecule Live · refreshed every 30 min

Target snapshot

tranexamic acid (Exacyl®) (tranexamic acid (Exacyl®)) — Institut Kassab d'Orthopédie. Tranexamic acid works by inhibiting the activation of plasminogen to plasmin, thereby preventing the breakdown of fibrin clots.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
tranexamic acid (Exacyl®) TARGET	tranexamic acid (Exacyl®)	Institut Kassab d'Orthopédie	phase 3	Antifibrinolytic	Lysine receptor on plasminogen
Trasylol	APROTININ	Bayer	marketed	Antifibrinolytic Agent	Plasminogen	1993-01-01
Cyklokapron	TRANEXAMIC ACID	Exela Pharma	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1986-01-01
Amicar	AMINOCAPROIC ACID	Epic Pharma Llc	marketed	Antifibrinolytic Agent [EPC]	Plasminogen	1964-01-01
Tranexamic Acid Irrigation	Tranexamic Acid Irrigation	University of Wisconsin, Madison	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
Tranexamic Acid Dosage 1	Tranexamic Acid Dosage 1	Chinese Academy of Medical Sciences, Fuwai Hospital	marketed	Antifibrinolytic agent	Plasminogen / Plasmin
aPCC, aPCC + TXA	aPCC, aPCC + TXA	Oslo University Hospital	marketed	Prothrombin complex concentrate with antifibrinolytic agent	Vitamin K-dependent clotting factors (II, VII, IX, X); plasminogen

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antifibrinolytic class)

Ain Shams University · 1 drug in this class
Bayer · 1 drug in this class
German Heart Center · 1 drug in this class
Institut Kassab d'Orthopédie · 1 drug in this class
Miller Orthopedic Specialists · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). tranexamic acid (Exacyl®) — Competitive Intelligence Brief. https://druglandscape.com/ci/tranexamic-acid-exacyl. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing